CRP与铁蛋白联合EASIX评分预测CAR-T相关毒性
本研究在171例接受axi-cel治疗的大B细胞淋巴瘤患者中,评估淋巴细胞清除前EASIX及实验室指标与CAR-T后细胞因子释放综合征(CRS)和免疫效应细胞相关神经毒性综合征(ICANS)的关联。EASIX联合铁蛋白(EASIX-F)可分层预测2-4级CRS,EASIX联合CRP和铁蛋白(EASIX-FC)可分层预测2-4级ICANS。
要点
- EASIX-F将2-4级CRS累积发生率分为74%、49%和23%三组。
- EASIX-FC将2-4级ICANS累积发生率分为74%、51%和29%三组。
- 淋巴细胞清除前常见实验室指标有助于CAR-T毒性临床决策。
核心结论
- 淋巴细胞清除前EASIX联合铁蛋白或联合CRP和铁蛋白可预测CAR-T相关CRS和ICANS风险。
研究设计与样本
- 前瞻性收集171例接受axicabtagene ciloleucel治疗的大B细胞淋巴瘤患者的毒性数据。
主要发现
- 2-4级CRS发生于81例(47%)患者,2-4级ICANS发生于84例(49%)患者。
- EASIX-F分层三组2-4级CRS累积发生率分别为74%(HR 4.8;95%CI 2.1-11;P<.001)、49%(HR 2.3;95%CI 1.02-5;P=.04)和23%(参照)。
- EASIX-FC分层三组2-4级ICANS累积发生率分别为74%(HR 3.6;95%CI 1.9-6.9;P<.001)、51%(HR 2.1;95%CI 1.1-3.9;P=.025)和29%(参照)。
临床怎么用
- 可用于支持临床决策,如抢先性毒性管理、住院时长和CAR-T给药场所选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Endothelial Activation and Stress Index (EASIX) score, defined as [(creatinine × lactate dehydrogenase [LDH])/platelets], is a marker of endothelial activation that has been validated in the allogeneic hematopoietic stem cell transplant setting. Endothelial activation is one of the mechanisms driving immune-mediated toxicities in patients treated with chimeric antigen receptor-T (CAR-T)-cell therapy. This study's objective was to evaluate the association between EASIX and other laboratory parameters collected before lymphodepletion and the subsequent onset of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) those patients. Toxicity data were collected prospectively on 171 patients treated with axicabtagene ciloleucel (axi-cel) for large B-cell lymphoma (LBCL). CRS grades 2 to 4 were diagnosed in 81 (47%) patients and ICANS grades 2 to 4 in 84 (49%). EASIX combined with ferritin (EASIX-F) identified 3 risk groups with CRS grades 2 to 4 cumulative incidence of 74% (hazards ratio [HR], 4.8; 95% confidence interval [CI], 2.1-11; P < .001), 49% (HR, 2.3; 95% CI, 1.02-5; P = .04), and 23% (reference), respectively. EASIX combined with CRP and ferritin (EASIX-FC) identified 3 risk groups with an ICANS grade 2 to 4 cumulative incidence of 74% (HR, 3.6; 95% CI, 1.9-6.9; P < .001), 51% (HR, 2.1; 95% CI, 1.1-3.9; P = .025), and 29% (reference). Our results indicate that common laboratory parameters before lymphodepletion correlate with CAR-T-related toxicities and can help support clinical decisions, such as preemptive toxicity management, hospitalization length, and proper setting for CAR-T administration.
引用
- Greenbaum U, Strati P, Saliba RM, et al. CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Adv. 2021. PMID: 34264268. doi:10.1182/bloodadvances.2021004575
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。